Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143
JNJ•Johnson & Johnson reported a 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC molecule.
1. Trial response rate
Johnson & Johnson reported a 75% tumor response rate in advanced prostate cancer with JNJ-6143, described as a first-in-class RIPTAC molecule.
